Update

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, announces that the Company's wholly-owned subsidiary, Trellus Health Inc., has entered into a $260,000 loan agreement ("Loan") with Mount Sinai Health System. The Loan extends the Group's cash runway until 31 July 2026.

As previously announced, the Board has engaged corporate restructuring advisors and continues its conversations with relevant parties around strategic options and opportunities for further funding, with such options including a possible sale of Trellus Health Inc., the Company's US subsidiary. There can be no certainty that any further funding will be forthcoming or transaction concluded nor as to terms thereon. The Board also continues to take action to protect wider stakeholders' interests.

Interest on the Loan, which is unsecured, will accrue at an annual rate of 8% with effect from 19 December 2026, payable on maturity of the Loan. The Loan falls due for repayment at the earlier of (i) 19 June 2027; or (ii) 90 days following the close of a sale of Trellus Health Inc.

The Company's ordinary shares remain suspended from trading on AIM effective 08 May 2026 pending clarification of the Company's financial position. Further announcements will be made as appropriate.

Related Party Transaction

The Loan by Mount Sinai Health System is deemed to be a related party transaction under AIM Rule 13 of the AIM Rules for Companies. The Company's Directors (excluding those who are connected to Mount Sinai) consider, having consulted with the Nominated Adviser, Singer Capital Markets, that the terms of the related party transaction are fair and reasonable insofar as the shareholders of the Company are concerned.